Long-Term Safety of Febuxostat in Subjects With Gout.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

116 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-03-31

Study Completion Date

2006-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD), in maintaining serum urate levels within clinically acceptable levels in subjects with gout.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout

NCT00174967

Gout

COMPLETED PHASE2

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

NCT00175019

Gout

COMPLETED PHASE3

Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

NCT00174915

Gout

COMPLETED PHASE3

Efficacy and Safety of Oral Febuxostat in Participants With Gout

NCT00430248

Gout

COMPLETED PHASE3

Safety and Efficacy of Oral Febuxostat in Subjects With Gout

NCT02082769

Gout

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Uric acid is the end product of purine degradation in humans. Hyperuricemia, a urate concentration in serum exceeding the limit of urate solubility (approximately 7.0 milligrams per deciliter \[mg/dL\]), is a common biochemical abnormality. Aberrations in any of the multiple mechanisms involved in the production and/or excretion of uric acid may increase serum urate concentrations, with persistent hyperuricemia as a marker for extracellular fluid monosodium urate supersaturation. As such, hyperuricemia is a necessary (but often not sufficient) risk factor for monosodium urate crystal deposition in tissues and is the fundamental pathophysiological process underlying the clinical manifestations of gout, which is a chronic disease characterized by urate crystal formation and deposition in joints and bones. Gout may progress from episodic attacks of acute inflammatory arthritis to a disabling chronic disorder characterized by deforming arthropathy; destructive deposits of urate crystals (tophi) in bones, joints, and other organs; structural and functional renal impairment due to interstitial urate crystal deposition; and urinary tract stones composed entirely or in part of uric acid crystals. Management of gout requires chronic treatment aimed at lowering serum urate into a subsaturating range (usually \<6.0 mg/dL) in which crystal formation and deposition are prevented or reversed.

Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout.

Subjects who want to participate in this study will have successfully completed study TMX-00-004 (NCT00174967).

All participants will initially receive an 80 mg dose. Dose titrations will occur in order to obtain and maintain clinically acceptable serum urate levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gout

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

Febuxostat

Intervention Type DRUG

Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.

2

Group Type EXPERIMENTAL

Febuxostat

Intervention Type DRUG

Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.

3

Group Type EXPERIMENTAL

Febuxostat

Intervention Type DRUG

Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Febuxostat

Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.

Intervention Type DRUG

Febuxostat

Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.

Intervention Type DRUG

Febuxostat

Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

TMX-67 Tei-6720 Uloric TMX-67 Tei-6720 Uloric TMX-67 Tei-6720 Uloric

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hyperuricemia (serum uric acid ≥8.0 mg/dL upon entering parent study TMX-00-004).
* Must meet American College of Rheumatology criteria for gout.
* Must have adequate renal function (serum creatinine \<1.5 mg/dL).
* Must have completed four weeks of double-blind dosing in Study TMX-00-004.
* Must not have experienced any serious study drug-related Adverse Events in Study TMX 00-004.
* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion Criteria

* History of xanthinuria
* Alcohol consumption \>14/week
* Has a History of significant concomitant illness
* Has active liver disease.
* Has a body mass index greater than 50 kg/m2
* Any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No